13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001121404
Total reported value
$534.0M
$534.0M
8 檔
54.7%
In Q4 2025, Sanofi's U.S. equity holdings reached a combined market value of $534.0M, distributed across 8 disclosed stock positions.
In Q4 2025, Sanofi adopted a defensive or profit-taking posture, trimming 0 positions and completely liquidating 2 holdings to manage risk exposure.
In terms of portfolio concentration, the top 5 core holdings (including MGTX, INBX, NVAX) accounted for 54.7% of total reported equity market value during Q4 2025.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | MGTX | MeiraGTx Holdings plc | Stock-Other | 31.24% | -0.58% | — | |
| 2 | INBX | Inhibrx Biosciences Inc | Stock-Other | 29.47% | -2.63% | — | |
| 3 | NVAX | Novavax Inc | Stock-Healthcare | 14.90% | -4.53% | — | |
| 4 | ANAB | Anaptysbio Inc | Stock-Other | 12.84% | +1.35% | — | |
| 5 | IMRX | Immuneering CORP - Class A | Stock-Other | 5.74% | -1.72% | — | |
| 6 | MPLT | Maplight Therapeutics Inc | Stock-Other | 5.16% | +0.60% | — | |
| 7 | ELDN | Eledon Pharmaceuticals Inc | Stock-Other | 0.40% | -0.75% | EXIT | |
| 8 | QTTB | Q32 Bio Inc | Stock-Other | 0.26% | +0.11% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | INBX | Inhibrx Biosciences Inc | +14.5% | — | Unchanged |
| 2 | ANAB | Anaptysbio Inc | +3.2% | — | Unchanged |
| 3 | QTTB | Q32 Bio Inc | +0.1% | — | Unchanged |
| 4 | ELDN | Eledon Pharmaceuticals Inc | -0.4% | — | Unchanged |
| 5 | IMRX | Immuneering CORP - Class A | -1.5% | — | Unchanged |
| 6 | MGTX | MeiraGTx Holdings plc | -7.3% | — | Unchanged |
| 7 | NVAX | Novavax Inc | -8% | — | Unchanged |
| 8 | MPLT | Maplight Therapeutics Inc | — | NEW | New buy |
| 9 | OMDA | Omada Health Inc | — | EXIT | Sold out |
| 10 | ✓ | Lava Therapeutics NV | — | EXIT | Sold out |
According to official SEC Form 13F filings, Sanofi reported a total U.S. public equity portfolio value of $534.0M across 8 disclosed positions in Q4 2025.
During Q4 2025, Sanofi's top holdings by market value included MGTX (31.2%)、INBX (29.5%)、NVAX (14.9%). The largest single position, MGTX, represented 31.2% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
MPLT
市值: $16.0M
Top Position Liquidated / Trimmed
OMDA
前期市值: $11.6M
In Q4 2025, Sanofi made 3 total portfolio adjustments, initiating 1 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 2 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.